News and Media

Publications and resources for members of the press.



Sumitomo Pharma Subsidiary Companies in the U.S., Including Sumitovant and its Wholly Owned Subsidiaries, to Combine and Form Sumitomo Pharma America

NEW YORK., April 3, 2023 – Sumitovant Biopharma Ltd. (“Sumitovant”) announced today that its parent  company Sumitomo Pharma Co., Ltd. (“Sumitomo Pharma”) will combine its wholly owned U.S.  subsidiaries to form Sumitomo Pharma America, Inc. (“Sumitomo Pharma America”). Sumitomo Pharma  America will combine Sumitovant and its wholly owned U.S. subsidiaries, Myovant Sciences, Inc.,  Urovant Sciences, […]

Sumitovant Biopharma Completes Acquisition of Myovant Sciences

NEW YORK and BASEL, Switzerland, March 10, 2023 /PRNewswire/ — Sumitovant Biopharma Ltd. (“Sumitovant”) and Myovant Sciences Ltd. (“Myovant”) announced today that Sumitovant has successfully completed its acquisition of Myovant originally announced October 23, 2022. Sumitovant has acquired all outstanding shares of Myovant not already owned by Sumitovant in an all-cash deal with a total […]

Myovant Sciences Announces Corporate Updates and Financial Results for Third Fiscal Quarter 2022

Third fiscal quarter 2022 total revenue of $100.2 million; including net product revenue of $61.4 million Net product revenue from U.S. sales of ORGOVYX® of $48.7 million in third fiscal quarter 2022, with sequential quarterly demand volume growth of 13% and cumulative patients estimated at 26,000 through December 2022 Net product revenue from U.S. sales of […]

Sumitovant Biopharma Helps Identify More Than 80 Peptide Drug Candidates for Neochromosome’s Differentiated Manufacturing Technology

NEW YORK – January 19, 2023 – Sumitovant Biopharma, Inc. (“Sumitovant”), a technology-driven biopharmaceutical company accelerating the development and commercialization of novel therapeutics, announced it has identified more than 80 peptide drug candidates for manufacturing, using the company’s DrugOME™ computational platform. As part of a collaboration with Neochromosome, Inc. (“Neochromosome”), Sumitovant used extensive natural language […]

Urovant Sciences® Announces Collaboration with Holly Robinson Peete to Help Raise Awareness for Overactive Bladder and Treatment Options

Urovant Sciences, Inc., and Holly Robinson Peete Collaborate to Bring Awareness to Overactive Bladder (OAB) Symptoms and Management Options as Part of the Time To Go™ Campaign Holly Robinson Peete Shares Her Experience Living with OAB and How Her Symptoms Have Improved Since Taking GEMTESA Approximately 33 Million Americans Experience Symptoms of OAB, Which Can […]

Enzyvant Announces Merger with Altavant

Combined company has full range of capabilities required to advance bold science for rare diseases in immunology and cardiopulmonology Cary, N.C., December 6, 2022 – Enzyvant Therapeutics, Inc. and Altavant Sciences, Inc., both wholly owned subsidiaries of Sumitovant Biopharma Ltd., today announced a merger to form a biopharmaceutical company focused on delivering life-altering therapies for […]

Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08

BASEL, Switzerland, Nov. 16, 2022 (GLOBE NEWSWIRE) — Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy, today announced that it approved equity awards for 18 new employees with a grant date of November 15, 2022 pursuant to Myovant’s 2020 Inducement Plan. The […]

Myovant Sciences Appoints Ann Tomlin as Senior Vice President of Human Resources

BASEL, Switzerland, Nov. 16, 2022 (GLOBE NEWSWIRE) — Myovant Sciences (NYSE: MYOV) today announced the appointment of Ann Tomlin as Senior Vice President of Human Resources. Beginning November 28, Ms. Tomlin will be responsible for developing talent solutions and human resources strategies across Myovant’s global functions. She will serve as a member of the Executive […]

Urovant Sciences® Announces Partnership with Thinx Inc. to Help Americans with Overactive Bladder This Travel Season

Urovant Sciences, Inc and Thinx, Inc Form a Unique Partnership Designed to Educate People Living with The Symptoms of Overactive Bladder (OAB) For Patients With OAB, Traveling or Enjoying a Night Out Can Be a Daunting Thought, Worrying Whether They Will Make it in Time to the Bathroom The Newly Launched Time to GoTM Campaign […]

Spirovant’s SP-101 pre-clinical data demonstrates great promise for individuals with cystic fibrosis (CF) who do not benefit from small molecule modulators

New pre-clinical data for SP-101, an investigational novel recombinant adeno-associated virus (AAV) gene therapy selected for its tropism to human airway epithelia for the treatment of people living with cystic fibrosis (CF), suggest co-administration of SP-101 with doxorubicin functionally corrects human CF airway epithelia by restoring chloride conductance to similar levels as non-CF or small […]

Urovant Sciences Announces Publication of Pharmacokinetic Data on GEMTESA® (Vibegron 75mg) Administered as an Intact or Crushed Tablet

A new peer-reviewed journal paper suggests that crushing GEMTESA (vibegron) 75-mg and taking it with applesauce may be an appropriate option for people with overactive bladder (OAB) and concommitant swallowing difficulties. Results from this Phase 1 study show that vibegron can be crushed and mixed with applesauce with no clinically meaningful change to pharmacokinetic (PK) […]

Myovant Sciences Announces Corporate Updates and Financial Results for Second Fiscal Quarter 2022

On October 23, 2022, Sumitovant Biopharma Ltd. (Sumitovant), in conjunction with parent company Sumitomo Pharma Co., Ltd. (Sumitomo Pharma), and Myovant Sciences (Myovant) announced that they have entered into a definitive agreement pursuant to which Sumitovant will acquire all outstanding shares of Myovant not already owned by Sumitovant for $27.00 per share in cash. This […]

Myovant Sciences Cancels Second Quarter Earnings Conference Call

BASEL, Switzerland, Oct. 24, 2022 (GLOBE NEWSWIRE) — Myovant Sciences (NYSE: MYOV) (“Myovant”) today announced the cancellation of its earnings conference call for the quarter ended September 30, 2022 that had originally been scheduled for October 26, 2022 at 5:00 p.m. Eastern Time. The call is being cancelled due to the announcement of the pending […]

Sumitovant Biopharma, Sumitomo Pharma, and Myovant Sciences Enter into Definitive Agreement

Sumitovant Biopharma to Acquire all Outstanding Shares of Myovant for $27 Per Share in Cash Combination Provides Expertise and Resources to Address Unmet Patient Needs in Women’s Health and Prostate Cancer Agreement Unanimously Recommended by Special Committee of Myovant’s Independent Directors and Approved by Board NEW YORK and BASEL, Switzerland and OSAKA, Japan, Oct. 23, 2022 /PRNewswire/ — Sumitovant Biopharma Ltd. (“Sumitovant”), in conjunction with […]

Sumitovant Biopharma and Sumitomo Pharma Announce Offer to Acquire Outstanding Shares of Myovant Sciences

NEW YORK and TOKYO October 2, 2022 — Sumitovant Biopharma Ltd. (“Sumitovant”), in conjunction  with parent company Sumitomo Pharma Co., Ltd. (“Sumitomo Pharma”), announced today it has  submitted a non-binding proposal (the “Proposal”) to the Audit Committee of the Board of Directors  (the “Audit Committee”) of Myovant Sciences Ltd. (“Myovant”) offering to acquire all outstanding […]

About Us

United in our mission to deliver breakthrough medicines to patients faster, we make Sumitovant greater than the sum of our parts.

Get to Know Us

News from Sumitovant Portfolio Companies